window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Chiesi Global Rare Diseases

  • Biotech & Pharma Business,Opinion & Events,Therapeutic Areas

    Chiesi launches second Find For Rare research grants programme at ERA 2026

    Chiesi Global Rare Diseases has launched the second edition of [...]

    June 9, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Pegunigalsidase alfa every four weeks dosing backed by CHMP for adult Fabry patients

    The European Medicines Agency’s Committee for Medicinal Product for Human [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Chiesi and Arbor partner on rare disease gene editing programmes targeting PH1 and other liver disorders

    Chiesi Group has entered into an exclusive global partnership with [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Natus expands AI-powered EEG analysis across Europe
    Categories: Central Nervous System, Digital & Data, Medical devices
  • Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma
    Categories: Advanced Therapies, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top